Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annika Nelde

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
Molecular & Cellular Proteomics : MCP|January 16, 2020
Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical TherapiesMichael Ghosh, Marion Gauger, Ana Marcu, et al.
Cancers|May 14, 2022
HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer PatientsChristian M Tegeler, Jonas Scheid, Hans-Georg Rammensee, et al.
Cancers|July 12, 2020
HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell TransplantationMalte Roerden, Annika Nelde, Jonas S Heitmann, et al.
Science Immunology|November 1, 2022
Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccinationYacine Maringer, Annika Nelde, Sarah M Schroeder, et al.
Leukemia & Lymphoma|March 2, 2021
Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcomeMalte Roerden, Melanie Märklin, Helmut R Salih, et al.
Cancer Immunology, Immunotherapy : CII|June 25, 2021
Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivoAnja Tatjana Teck, Sabrina Urban, Petra Quass, et al.
Cancer Immunology, Immunotherapy : CII|March 12, 2020
Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivoAnja Tatjana Teck, Sabrina Urban, Petra Quass, et al.
Leukemia & Lymphoma|January 4, 2018
Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancersJuliane Sarah Walz, Daniel Johannes Kowalewski, Linus Backert, et al.
AIDS (London, England)|June 6, 2020
HIV-1 induced changes in HLA-C*03 :  04-presented peptide repertoires lead to reduced engagement of inhibitory natural killer cell receptorsMaja C Ziegler, Annika Nelde, Jeffrey K Weber, et al.
Journal of Proteome Research|October 8, 2019
MHCquant: Automated and Reproducible Data Analysis for ImmunopeptidomicsLeon Bichmann, Annika Nelde, Michael Ghosh, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Molecular & Cellular Proteomics : MCP|January 16, 2020
Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical TherapiesMichael Ghosh, Marion Gauger, Ana Marcu, et al.
Cancers|May 14, 2022
HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer PatientsChristian M Tegeler, Jonas Scheid, Hans-Georg Rammensee, et al.
Cancers|July 12, 2020
HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell TransplantationMalte Roerden, Annika Nelde, Jonas S Heitmann, et al.
Science Immunology|November 1, 2022
Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccinationYacine Maringer, Annika Nelde, Sarah M Schroeder, et al.
Leukemia & Lymphoma|March 2, 2021
Expression levels of HLA-DR in acute myeloid leukemia: implications for antigenicity and clinical outcomeMalte Roerden, Melanie Märklin, Helmut R Salih, et al.
Cancer Immunology, Immunotherapy : CII|June 25, 2021
Correction to: Cancer testis antigen Cyclin A1 harbors several HLA‑A*02:01‑restricted T cell epitopes, which are presented and recognized in vivoAnja Tatjana Teck, Sabrina Urban, Petra Quass, et al.
Cancer Immunology, Immunotherapy : CII|March 12, 2020
Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivoAnja Tatjana Teck, Sabrina Urban, Petra Quass, et al.
Leukemia & Lymphoma|January 4, 2018
Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancersJuliane Sarah Walz, Daniel Johannes Kowalewski, Linus Backert, et al.
AIDS (London, England)|June 6, 2020
HIV-1 induced changes in HLA-C*03 :  04-presented peptide repertoires lead to reduced engagement of inhibitory natural killer cell receptorsMaja C Ziegler, Annika Nelde, Jeffrey K Weber, et al.
Journal of Proteome Research|October 8, 2019
MHCquant: Automated and Reproducible Data Analysis for ImmunopeptidomicsLeon Bichmann, Annika Nelde, Michael Ghosh, et al.
Pageof 6